《生命科学》 2014, 26(8): 823-828

死亡相关凋亡诱导蛋白激酶2 (DRAK2)研究进展

李仲诚1，阮礼波1，杨　帆1，李静雅2，李　佳2*，汤　杰1*

(1 华东师范大学小分子药物研究所，上海 200062；2 中国科学院上海药物研究所，国家新药筛选中心，上海 201203)

摘　要：摘　要：死亡相关凋亡诱导蛋白激酶2 (death associated protein related apoptotic kinase 2， DRAK2) 为苏氨酸/丝氨酸激酶，属于死亡相关蛋白激酶家族中的一员，是凋亡的正性调节因子之一。近年来研究发现，DRAK2 与T 细胞生存分化、胰岛β 细胞生存、癌细胞生长息息相关，已成为治疗自身免疫性疾病、糖尿病、器官移植排斥以及癌症的潜在药物靶点，但其具体的细胞作用机制及信号通路尚不明确。对近年来DRAK2激酶的生物学功能及相应抑制剂的研究进展进行简要综述。

Study of the DRAK2

LI Zhong-Cheng1， RUAN Li-Bo1， YANG Fan1， LI Jing-Ya2， LI Jia2*， TANG Jie1*

(1 Institute of Drug Discovery and Development， East China Normal University， Shanghai 200062， China; 2 National Center for Drug Screening， Shanghai Institute of Materia Medica， Chinese Academy of Science， Shanghai 201203， China)

Abstract: Abstract: Death associated protein related apoptotic kinase 2 (DRAK2) is a serine/threonine kinase belonging to death associated protein (DAP) kinase family that have been implicated in regulation of apoptosis. Recent researches have indicated that DRAK2 plays critical roles in T-cell survival and differentiation， islet cell apoptosis， tumor initiation， however， little is known about the exactly underlying mechanisms. The studies suggest that inhibition of DRAK2 has therapeutic potential for autoimmune disease， diabetes， rejection of transplanted organs and cancers. In this paper， the progress of the biological functions and inhibitors on DRAK2 is reviewed.